Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data
This study used Pentavere's previously validated artificial intelligence (AI) to extract real-world data on the treatment patterns and outcomes of patients receiving CDK4/6i+endocrine therapy (ET) for HR+/HER2- ABC/MBC at Sinai Health in Toronto, Canada. Between 1 January 2016 and 1 July 2021, 48 patients were diagnosed with HR+/HER2- ABC/MBC and received CDK4/6i + ET. A total of 38 out of 48 patients received CDK4/6i + ET in 1L, of which 34 of the 38 (89.5%) received palbociclib + ET. In 2L, 12 of the 21 (57.1%) patients received CDK4/6i + ET, of which 58.3% received abemaciclib. In 3L, most patients received chemotherapy...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Ruth Moulson Guillaume Feug ère Tracy S Moreira-Lucas Florence Dequen Jessica Weiss Janet Smith Christine Brezden-Masley Source Type: research
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Cancer Research - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane
ConclusionTo the best of our knowledge, we present here for the first time a comprehensive and direct head-to-head, intra-patient-cross-over comparison of the aromatase inhibitor letrozole and the aromatase inactivator exemestane concerning their ability to suppress serum estrogen levels in vivo. All in all, our results clearly demonstrate that letrozole therapy results in a more profound suppression of serum E1 and E2 levels compared to exemestane. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 23, 2024 Category: Cancer & Oncology Source Type: research
Estrogen receptor alpha mutations, truncations, heterodimers, and therapies
Endocrinology. 2024 Apr 21:bqae051. doi: 10.1210/endocr/bqae051. Online ahead of print.ABSTRACTAnnual breast cancer (BCa) deaths have declined since its apex in 1989 concomitant with widespread adoption of hormone therapies that target estrogen receptor alpha (ERα), the prominent nuclear receptor expressed in ∼80% of BCa. However, up to ∼50% of ER + patients with high-risk disease experience post endocrine therapy relapse and metastasis to distant organs. The vast majority of BCa mortality occurs in this setting, highlighting the inadequacy of current therapies. Genomic abnormalities to ESR1, the gene encoding ERα, e...
Source: Endocrinology - April 21, 2024 Category: Endocrinology Authors: Govinda R Hancock Jason Gertz Rinath Jeselsohn Sean W Fanning Source Type: research
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study
CONCLUSION: The addition of palbociclib to ET was effective for treating HR+/HER2- ABC in Japanese routine clinical practice.PMID:38642245 | DOI:10.1007/s12282-024-01575-5 (Source: Breast Cancer)
Source: Breast Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Tetsuhiro Yoshinami Shigenori E Nagai Masaya Hattori Takuho Okamura Kenichi Watanabe Takahiro Nakayama Hiroko Masuda Michiko Tsuneizumi Daisuke Takabatake Michiko Harao Hiroshi Yoshino Natsuko Mori Hiroyuki Yasojima Chiya Oshiro Madoka Iwase Miki Yamaguch Source Type: research
PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ER α stability
In conclusion, these data suggest that PFKFB3 is identified as an adverse prognosis factor for ER-positive breast cancer and plays a previously unrecognized role in the regulation of ERα stability and activity. Our results further explores an effective approach to improve fulvestrant sensitivity through the early combination with a PFKFB3 inhibitor.PMID:38640982 | DOI:10.1016/j.cellsig.2024.111184 (Source: Cellular Signalling)
Source: Cellular Signalling - April 19, 2024 Category: Cytology Authors: Wenzhi Jia Qianyun Wu Mengqin Shen Xiaofeng Yu Shuxian An Li Zhao Gang Huang Jianjun Liu Source Type: research
Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors
British Journal of Cancer, Published online: 18 April 2024; doi:10.1038/s41416-024-02680-0Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors (Source: British Journal of Cancer)
Source: British Journal of Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Ching-Yuan Chang Bobby L. Jones Juan M. Hincapie-Castillo Haesuk Park Coy D. Heldermon Vakaramoko Diaby Debbie L. Wilson Wei-Hsuan Lo-Ciganic Source Type: research
Community cohesion looseness in gene networks reveals individualized drug targets and resistance
Brief Bioinform. 2024 Mar 27;25(3):bbae175. doi: 10.1093/bib/bbae175.ABSTRACTCommunity cohesion plays a critical role in the determination of an individual's health in social science. Intriguingly, a community structure of gene networks indicates that the concept of community cohesion could be applied between the genes as well to overcome the limitations of single gene-based biomarkers for precision oncology. Here, we develop community cohesion scores which precisely quantify the community ability to retain the interactions between the genes and their cellular functions in each individualized gene network. Using breast can...
Source: Briefings in Bioinformatics - April 15, 2024 Category: Bioinformatics Authors: Seunghyun Wang Doheon Lee Source Type: research
Nipple-Sparing Mastectomy and Adequate Margins for Patients With Ductal Carcinoma In Situ
DISCUSSION: No specific margin status was found to correlate with recurrence for patients with DCIS or DCIS + MI undergoing NSM, with an altogether low recurrence risk. Overall, this suggests that recommended DCIS margins in BCS doesn't necessarily apply in NSM, where margins of <2 mm may be acceptable.PMID:38605446 | DOI:10.1177/00031348241246179 (Source: The American Surgeon)
Source: The American Surgeon - April 12, 2024 Category: Surgery Authors: Kristina Shaffer Lilian Harris Stephanie Ng Judy A Tjoe Source Type: research
Nipple-Sparing Mastectomy and Adequate Margins for Patients With Ductal Carcinoma In Situ
DISCUSSION: No specific margin status was found to correlate with recurrence for patients with DCIS or DCIS + MI undergoing NSM, with an altogether low recurrence risk. Overall, this suggests that recommended DCIS margins in BCS doesn't necessarily apply in NSM, where margins of <2 mm may be acceptable.PMID:38605446 | DOI:10.1177/00031348241246179 (Source: The American Surgeon)
Source: The American Surgeon - April 12, 2024 Category: Surgery Authors: Kristina Shaffer Lilian Harris Stephanie Ng Judy A Tjoe Source Type: research
Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials
Breast. 2024 Apr 4;75:103729. doi: 10.1016/j.breast.2024.103729. Online ahead of print.ABSTRACTOver the past few decades, first-line therapy for treating advanced and metastatic HR+/HER2-breast cancer has transformed due to the introduction of adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i). However, there is an unmet need for novel classes of endocrine therapy with superior efficacy to improve treatment outcomes and overcome CDK4/6i resistance. New generation selective estrogen receptor degraders (SERDs), orally administered and with higher bioavailability, could potentially be the novel ...
Source: Breast - April 10, 2024 Category: Cancer & Oncology Authors: Kleoniki Apostolidou Eleni Zografos Maria Alkistis Papatheodoridi Oraianthi Fiste Meletios Athanasios Dimopoulos Flora Zagouri Source Type: research
The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer
CONCLUSIONS: Nonadherence was high in the current sample, and significantly more likely in participants reporting overall severe symptoms. Clinicians should be aware of the scale of common side effects and facilitate open conversation about potential barriers to adherence. Follow-up care should include assessment of common symptoms and signpost patients to appropriate support or treatment when required. Future research should explore potential for a central symptom to act as a target for intervention, to relieve overall side effect burden and facilitate better medication adherence.PMID:38599048 | DOI:10.1016/j.breast.2024....
Source: Breast - April 10, 2024 Category: Cancer & Oncology Authors: Sommer Agnew Megan Crawford Iain MacPherson Victor Shiramizu Leanne Fleming Source Type: research
Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature
CONCLUSION: The study showed that a subgroup of patients with a clinical high risk and a genomic low risk ER+/HER2-breast cancer benefits from NET resulting in BCS instead of a mastectomy. Additionally, NET may enable de-escalation in axillary treatment.PMID:38599047 | DOI:10.1016/j.breast.2024.103726 (Source: Breast)
Source: Breast - April 10, 2024 Category: Cancer & Oncology Authors: Josefien P van Olmen Chaja F Jacobs Sanne A L Bartels Claudette E Loo Joyce Sanders Marie-Jeanne T F D Vrancken Peeters Caroline A Drukker Frederieke H van Duijnhoven Marleen Kok Source Type: research
Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance
Cancer Discov. 2024 Apr 10:OF1-OF3. doi: 10.1158/2159-8290.CD-24-0282. Online ahead of print.ABSTRACTRosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well as in its reawakening. Targeting these epigenetic changes blocks the entrance to dormancy and reduces the persister cancer cell population, enhancing the cytotoxic effects of ET in vitro. See related article by Rosano et al. (9).PMID:38598672 | DOI:10.1158/2159-8290.CD-24-0282 (Source: Cancer Control)
Source: Cancer Control - April 10, 2024 Category: Cancer & Oncology Authors: Arnau Llinas-Bertran Meritxell Bellet-Ezquerra Jose A Seoane Source Type: research
